Clinical Trial: Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07140900) titled 'Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer' on Aug. 21.

Brief Summary: The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.

Study Start Date: Sept. 29

Study Type: INTERVENTIONAL

Condition: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Intervention: DRUG: Xaluritamig

Participants will receive xaluritamig intravenously.

DRUG: Darolutamide

Participants will receive darolutamide orally. ...